

Company	Compound	Phase	Indication & Inclusion Criteria	Locations	Clinical Trial
<b>Exon Skipping</b>					
<a href="#">Dyne Therapeutics</a>	DYNE-251	Phase I & II	Duchenne Muscular Dystrophy 4 Years to 16 Years Amenable to skipping Exon 51	USA (CA, CO, GA, MA, OH, OR, PA, TN, UT, VA) AUS, BEL, CAN, IRL, ITA, KOR, ESP, GBR	<a href="#">NCT05524883</a> ( <a href="#">DELIVER</a> )
<a href="#">PepGen</a>	CONNECT1-EDO51	Phase II	Duchenne Muscular Dystrophy 8 Years and up Amenable to skipping Exon 51	CAN	<a href="#">NCT06079736</a> ( <a href="#">CONNECT1-EDO51</a> )
<a href="#">NS Pharma</a> <a href="#">Nippon Shinyaku</a>	NS-089/ NCNP-02	Phase II	Duchenne Muscular Dystrophy 4 Years to 14 years Ambulatory Amenable to exon 44 skipping	USA (CO, GA, IL, KS, OH, OR, PA, TX, VA)	<a href="#">NCT05996003</a>
<a href="#">NS Pharma</a> <a href="#">Nippon Shinyaku</a>	NS-050/ NCNP-03	Phase I & II	Duchenne Muscular Dystrophy 4 Years to 14 years Ambulatory Amenable to exon 50 skipping	USA (CA, CO, IL, KS, OR, PA) JPN	<a href="#">NCT06053814</a> ( <a href="#">Meteor50</a> )
<a href="#">BioMarin Pharmaceutical</a>	BMN 351	Phase I & II	Duchenne Muscular Dystrophy 4 Years to 10 years Ambulatory Amenable to exon 51 skipping	ITA, NLD, ESP, GBR, TUR	<a href="#">NCT06280209</a>
<a href="#">Avidity Biosciences</a>	AOC 1044	Phase II	Duchenne Muscular Dystrophy 7 Years to 27 Years Amenable to skipping Exon 44 Open-label extension	USA (AR, CA, GA, MA, MN, NC, OH, TX)	<a href="#">NCT06244082</a> ( <a href="#">EXPLORE44OLE</a> )
<a href="#">Peking Union Medical College Hospital</a> <a href="#">GenAssist</a>	GEN6050X	Phase I	Duchenne Muscular Dystrophy 4 Years to 10 Years Ambulatory with specific DMD exon deletion types	CHN	<a href="#">NCT06392724</a> ( <a href="#">GEN6050XIIT</a> )
<b>Gene Therapy</b>					
<a href="#">Sarepta</a>	SRP-9001 (Delandistrogene Moxeparvovec)	Phase III	Duchenne Muscular Dystrophy Non-ambulatory or Ambulatory 8 Years to 18 Years	USA (AR, CA, FL, IL, IA, MD, MA, MO, NY, NC, OH, PA, VA) AUS, BEL, DEU, HKG, ISR, ITA, JPN, ESP, SWE, TWN, GBR	<a href="#">NCT05881408</a> ( <a href="#">ENVISION</a> )
<a href="#">Sarepta</a>	Gene Therapy long- term follow-up	Phase IV	Duchenne Muscular Dystrophy Patients have been prescribed delandistrogene moxeparvovec	USA (AK, CO, DC, FL, IN, KS, MI, PA, TN, TX, VA)	<a href="#">NCT06270719</a> ( <a href="#">ENDURE</a> )

<a href="#">Sarepta</a>	SRP-9001 (Delandistrogene Moxeparvovec)	Phase I	Duchenne Muscular Dystrophy Patients with pre-existing AAV Abs 4 Years to 8 Years	USA(MO)	<a href="#">NCT06597656</a> ( <a href="#">HORIZON</a> )
<a href="#">Roche</a>	Delandistrogene Moxeparvovec	Phase II	Duchenne Muscular Dystrophy Up to 4 Years Mutation between Exons 18 and 79	BEL, DEU, FRA, ITA, ESP, GBR	<a href="#">NCT06128564</a> ( <a href="#">ENVOL</a> )
<a href="#">RegenexBio</a>	RGX-202	Phase I & II	Duchenne Muscular Dystrophy 1 Year to 11 Years Ambulatory Mutation in Exons 18 and above	USA (AR, CA, IL, TX, VA)	<a href="#">NCT05693142</a> ( <a href="#">AFFINITY DUCHENNE</a> )
<a href="#">Solid Biosciences</a>	SGT-003	Phase I & II	Duchenne Muscular Dystrophy 4 Years to 8 Years Ambulatory	USA (AR, CA, OH, VA) CAN	<a href="#">NCT06138639</a> ( <a href="#">INSPIRE DUCHENNE</a> )
<b>Muscle Stabilizer</b>					
<a href="#">Edgewise Therapeutics</a>	EDG-5506	Phase II	Becker Muscular Dystrophy 12 Years to 50 Years Ambulatory	USA (AR, CA, CO, FL, GA, IL, IN, IA, KS, MD, MA, MO, MN, NY, NC, OH, PA, TX, VA) AUS, BEL, DNK, FRA, DEU, ISR, ITA, NLD, NZL, ESP, GBR	<a href="#">NCT05291091</a> ( <a href="#">GRAND CANYON</a> )
<a href="#">Edgewise Therapeutics</a>	EDG-5506	Phase II	Duchenne Muscular Dystrophy 6 Years to 14 Years Ambulatory Previous treated with an AAV-based gene therapy	USA (CA, FL, MA, MO, NC, OH)	<a href="#">NCT06100887</a> ( <a href="#">FOX</a> )
<b>Cell Therapy</b>					
<a href="#">Capricor</a>	CAP-1002	Phase III	Duchenne Muscular Dystrophy 10 Years and older	USA (AR, AZ, CA, CO, GA, IA, IL, MA, MO, NY, NC, OH, TX, UT, VA, WA, WI)	<a href="#">NCT05126758</a> ( <a href="#">HOPE-3</a> )
<b>Anti-inflammatory</b>					
<a href="#">Nationwide Children's Hospital</a> <a href="#">Children's Hospital of Chicago</a> <a href="#">Children's Hospital Medical Center, Cincinnati</a>	Prednisolone	Phase IV	Duchenne Muscular Dystrophy 1 Month to 30 Months	USA (IL, OH, TX, VA)	<a href="#">NCT05412394</a>

<a href="#">University of Florida</a> <a href="#">U.S. Army Medical Research and Development Command</a>	Prednisone	Phase II	Duchenne Muscular Dystrophy 5 Years to 8 Years Ambulatory	USA (FL)	<a href="#">NCT04322357</a>
<b>Cardiac Function</b>					
<a href="#">Medical University of Gdansk</a>	Metoprolol Succinate	Phase III	Duchenne Muscular Dystrophy 8 Years to 17 Years	POL	<a href="#">NCT05066633</a>
<b>Others</b>					
<a href="#">Italfarmaco</a>	Givinostat	Phase III	Duchenne Muscular Dystrophy Years 9 to 17 years Non-ambulant	BEL, CAN, FRA, DEU, ITA, NLD, GBR	<a href="#">NCT05933057</a>
<a href="#">Sqy Therapeutics</a>	SQY51	Phase I & IIa	Duchenne Muscular Dystrophy 6 Years and older ≥ 16 kg body weight Amenable to exon-51 skipping	FRA	<a href="#">NCT05753462</a> <a href="#">(AVANCE1)</a>
<a href="#">Roche</a>	Satralizumab	Phase II	Duchenne Muscular Dystrophy 8 Years to 15 Years Additional criteria for fracture-naïve and low-trauma fractures participants	USA (MI, TX, VA) ITA, POL, ESP	<a href="#">NCT06450639</a> <a href="#">(SHIELD DMD)</a>
<a href="#">Satellos</a>	SAT-3247	Early Phase 1	Healthy volunteers (HVs) and adult participants with DMD	AUS	<a href="#">NCT06565208</a>